Skip to main content

Table 5 Head to head relative treatment effects expressed as odds ratios (mean, 95% CrI)

From: The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

  Dasatinib 100 mg Nilotinib 600 mg Nilotinib 800 mg
CCyR (6 months)
Dasatinib 100 mg N/A 0.76 (0.1, 9.31) 0.91 (0.12, 10.58)
Nilotinib 600 mg 1.32 (0.11, 9.58) N/A 1.2 (0.23, 5.5)
Nilotinib 800 mg 1.10 (0.09, 8.29) 0.84 (0.18, 4.27) N/A
CCyR (12 months)
Dasatinib 100 mg N/A 0.95 (0.41, 2.22) 1.09 (0.47, 2.60)
Nilotinib 600 mg 1.05 (0.45, 2.43) N/A 1.15 (0.58, 2.32)
Nilotinib 800 mg 0.92 (0.38, 2.13) 0.87 (0.43, 1.73) N/A
CCyR (18 months)
Dasatinib 100 mg N/A 0.77 (0.44, 1.36) 0.95 (0.54, 1.66)
Nilotinib 600 mg 1.30 (0.73, 2.29) N/A 1.23 (0.79, 1.92)
Nilotinib 800 mg 1.05 (0.60, 1.84) 0.81 (0.52, 1.27) N/A
MMolR (12 months)
Dasatinib 100 mg N/A 0.74 (0.45, 1.19) 0.76 (0.47, 1.22)
Nilotinib 600 mg 1.35 (0.84, 2.20) N/A 1.04 (0.74, 1.45)
Nilotinib 800 mg 1.31 (0.82, 2.13) 0.96 (0.69, 1.35) N/A